How can I regain to my sex drive?

 

Q: Ever since I have had breast cancer, my sex drive has been nonexistent. This was not the case before and my husband is getting frustrated with me. I understand how he can feel this way, but I have no desire to be intimate. I feel like an asexual being and not a woman. How can I return to my normal self? I feel like a different person and I want the old me back. Will that ever happen?

A: Certain cancer treatments may affect your sexual functioning. Women who have their ovaries surgically removed may experience a lowered sex drive as the amount of testosterone produced in their bodies drop. Some types of chemotherapy, radiation, and medications can produce vaginal irritation and pain. Men may experience problems with erections following prostate surgery or external beam radiation. Chemotherapy and other treatments can damage nerves that affect penile sensation.

Psychological factors take a toll on your sex life as well. Surgical alterations, such as mastectomy or colostomy, can leave you feeling as if you are sexually undesirable. The rigors of all types of treatment might cause you to feel exhausted, nauseated, anxious, or depressed—not the best frame of mind for sexual expression. Talk about your problems or concerns with the professionals on your health care team. Their knowledge and experience can help you regain an enjoyable sex life.

--Kathy Newman, RN, BSN

Sometimes, treatment can lead to long-term sexual side effects.

Latest Cancer News
Oncotype DX® Predicts Recurrence Risk in Node-negative and Node-positive Breast Cancer Treated with Tamoxifen or Anastrozole

March 10, 2010 — Researchers affiliated with the TransATAC Study have reported that the Oncotype DX® test predicts the risk of distant cancer recurrence in postmenopausal women with early, hormone receptor-positive breast cancer with both node-negative and node-positive disease treated with tamoxifen (Nolvadex®) or anastrozole (Arimidex®). These results were published early online in the Journal of Clinical Oncology on March 8, 2010.

Recent Results of High-dose Proleukin® for Metastatic Renal Cell Carcinoma Reported

March 10, 2010 — Researchers involved in a U.S. multicenter trial (Cytokine Working Group) have reported that high-dose Proleukin® (aldesleukin, interleukin-2, IL-2) results in a higher response rate in patients with metastatic renal cell carcinoma (MRCC) than historically reported. The details of this study were presented at the 2010 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, March 5-7, in San Francisco.

Cystoscopy Remains Best Method for Surveillance of Patients with Bladder Cancer

March 10, 2010 — Researchers from the M. D. Anderson Cancer Center have reported that cystoscopy alone remains the most cost-effective method of detecting recurrent superficial bladder cancer. The details of this study were presented at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium March 5-7 in San Francisco.

Select news items provided by Reuters Health